BVF Partners, a fundamental equity hedge fund, led a $225m Series B funding round in AltruBio, a company focused on developing targeted antibody therapeutics for the treatment of cancer and immune related inflammatory diseases, with participation from RA Capital Management, Cormorant Asset Management, Soleus Capital, Delos Capital, aMoon Fund and Blackstone Multi-Asset Investing. “Treatment options remain limited in many autoimmune conditions, including moderate to severe ulcerative colitis, and novel mechanisms are sorely needed. We are excited to support AltruBio and their commitment to developing a potential first-in-class medicine across multiple autoimmune indications, starting with UC,” Gorjan Hrustanovic, BVF Partners Managing Director.